Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Biogen Options Stroke Drug from TMS

Biogen, headquartered in Cambridge, Massachusetts, signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.

Read More »

Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures

Pfizer Inc. announced plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.

Read More »

Nature Cell and Biostar Stem Cell Research Institute Begin World’s First Stem Cell-Based Regenerative Treatment for Alzheimer’s Disease in Japan

South Korea’s Biostar Stem Cell Research Institute – jointly operated by Nature Cell and Rbio – announced that Trinity Clinic Fukuoka, a partner hospital in Japan, received approval for the application of regenerative medicine in Alzheimer’s disease and officially began stem cell treatment as of April 12.

Read More »

Alzheon Launches IPO to Fund Alzheimer’s Drug

Alzheon, based in Framingham, Massachusetts, filed with the U.S. Securities and Exchange Commission to launch an initial public offering (IPO).

Read More »

AbbVie’s Elagolix Hits Primary Endpoints for Uterine Fibroids

AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.

Read More »

AbbVie, Voyager Launch Alzheimer’s Partnership

Chicago-based AbbVie and Cambridge, Mass.-based Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.

Read More »

U.S. FDA looks to pave way for earlier-stage Alzheimer’s drugs

U.S. regulators proposed lowering the bar for clinical trial success for experimental Alzheimer’s drugs.

Read More »

Biogen Plunges After Making Changes to Alzheimer’s Drug Trial

At the Leerink Healthcare Conference, Biogen chief medical officer Al Sandrock shook up investors by saying the company added 510 more patients to its clinical trial of aducanumab in Alzheimer’s disease.

Read More »

Biogen stops testing Tysabri to treat stroke after study fails

Biogen Inc. will stop testing the company’s established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study.

Read More »

“Not All Amyloid Beta Therapeutics Are Created Equal”

ProMIS Neurosciences Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom